Search results for "immunity"

showing 7 items of 1537 documents

Mast cells as protectors of health.

2019

Mast cells (MCs), which are well known for their effector functions in T(H)2-skewed allergic and also autoimmune inflammation, have become increasingly acknowledged for their role in protection of health. It is now clear that they are also key modulators of immune responses at interface organs, such as the skin or gut. MCs can prime tissues for adequate inflammatory responses and cooperate with dendritic cells in T-cell activation. They also regulate harmful immune responses in trauma and help to successfully orchestrate pregnancy. This review focuses on the beneficial effects of MCs on tissue homeostasis and elimination of toxins or venoms. MCs can enhance pathogen clearance in many bacter…

tumorImmunologyvenomTryptaseMast cell; innate immunity; infection; mast cell protease; tumor; pregnancy; venom; toxin; central nervous system traumaInfectionsCell DegranulationMast Cell ; Innate Immunity ; Infection ; Mast Cell Protease ; Tumor ; Pregnancy ; Venom ; Toxin ; Central Nervous System TraumaImmune systemCathelicidinsPregnancymedicineImmunology and AllergyAnimalsHomeostasisHumansEmbryo ImplantationMast CellsCNS traumatoxininnate immunityTissue homeostasismast cell proteaseToll-like receptorTumor microenvironmentInnate immune systembiologybusiness.industryDegranulationMast cellhumanitiesImmunity InnateToll-Like Receptor 2infectionddc:medicine.anatomical_structureImmunologybiology.proteinFemalepregnancybusinessmast cell

researchProduct

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

2020

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

unstable anginaMyocardial ischaemia[SDV]Life Sciences [q-bio]Vascular damage Radboud Institute for Health Sciences [Radboudumc 16]dual antithrombotic therapyGuidelineheparin030204 cardiovascular system & hematologyPlatelet inhibitionantiplatelet0302 clinical medicineST segmentMedicinedabigatranMyocardial infarctionguidelinesglycoprotein iib/iiia inhibitorsanticoagulationNon-ST Elevated Myocardial InfarctionrivaroxabanComputingMilieux_MISCELLANEOUSreproductive and urinary physiologydiabetesbleedingsbivalirudinatherothrombosiDisease ManagementangioplastyGuidelines • acute cardiac care • acute coronary syndrome • angioplasty • anticoagulation • antiplatelet • apixaban • aspirin • atherothrombosis • betablockers • bleedings • bivalirudin • bypass surgery • cangrelor • chest pain unit • clopidogrel • dabigatran • diabetes • dual antithrombotic therapy • early invasive strategy • edoxaban • enoxaparin • European Society of Cardiology • fondaparinux • glycoprotein IIb/ IIIa inhibitors • heparin • high-sensitivity troponin • minoca • myocardial ischaemia • myocardial infarction • nitrates • non-ST-elevation myocardial infarction • platelet inhibition • prasugrel • recommendations • revascularization • rhythm monitoring • rivaroxaban • stent • ticagrelor • triple therapy • unstable anginaenoxaparinGeneral MedicineClopidogrel3. Good healthearly invasive strategymyocardial infarctiontriple therapy030220 oncology & carcinogenesisHigh sensitivity troponinembryonic structuresCardiologyPlatelet aggregation inhibitorrevascularizationbiological phenomena cell phenomena and immunityCardiology and Cardiovascular MedicineTicagrelormedicine.drugHumanrecommendationAcute coronary syndromemedicine.medical_specialtyaspiringlycoprotein IIb/IIIa inhibitornon-ST-elevation myocardial infarctionapixabanrhythm monitoringEuropean Society of Cardiologyticagrelor03 medical and health sciencesnitrateatherothrombosisbetablockersInternal medicineacute cardiac careminocachest pain unitDiseases of the circulatory (Cardiovascular) systemHumansIn patientAcute Coronary SyndromeclopidogrelUnstable anginaurogenital systemnitratesbusiness.industryfondaparinuxbetablockerArrhythmias Cardiac030229 sport sciencesbleedingmedicine.diseasemyocardial ischaemiaplatelet inhibitionprasugreldiabeteGlycoprotein IIb/IIIa inhibitorsRC666-701bypass surgerySettore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARErecommendationsedoxabanhigh-sensitivity troponinstentbusinessPlatelet Aggregation Inhibitorscangrelor

researchProduct

Real-world experience with obeticholic acid in patients with primary biliary cholangitis

2021

Background & aims Obeticholic acid (OCA) is the second-line treatment approved for patients with primary biliary cholangitis (PBC) and an inadequate response or intolerance to ursodeoxycholic acid. We aimed to evaluate the effectiveness and safety of OCA under real-world conditions. Methods Patients were recruited into the Italian PBC Registry, a multicentre, observational cohort study that monitors patients with PBC at national level. The primary endpoint was the biochemical response according to Poise criteria; the secondary endpoint was the biochemical response according to normal range criteria, defined as normal levels of bilirubin, alkaline phosphatase (ALP), and alanine aminotransfer…

upper limit of normalCirrhosisALTAMAAutoimmunityantinuclear antibodiesULNPBCGastroenterologyUDCASettore MED/12ULN upper limit of normalobeticholic acidaRR adjusted risk ratio.CRFs case record formAST aspartate transferaseClinical endpointGGT gamma-glutamyl transferaseQCprimary biliary cholangitisGastroenterologyUrsodeoxycholic acidANATCCCirrhosisCholestasiTIPSTreatment Completer CohortANA antinuclear antibodiemedicine.medical_specialtyRRUDCA ursodeoxycholic acidTIPS transjugular intrahepatic portosystemic shuntOCACirrhosiALP alkaline phosphataseautoimmune hepatitismedicine.diseasedigestive system diseasesDiscontinuationKeywords: AIH autoimmune hepatitiQC quality controlchemistrygamma-glutamyl transferaserandomised controlled trialelectronic data captureantimitochondrial antibodiesaspartate transferaseAutoimmune hepatitischemistry.chemical_compoundAIHCRFsImmunology and Allergyadjusted risk ratioANA antinuclear antibodiesRR risk ratioOverall cohortALT alanine transferaseAMA antimitochondrial antibodieCholestasisCRFs case record formsObeticholic acidOverlap PBC-AIHursodeoxycholic acidOCA obeticholic acidTolerabilityalkaline phosphataseRCTResearch Articlemedicine.drugcase record formsContext (language use)AMA antimitochondrial antibodiesInternal medicineEDC electronic data capturetransjugular intrahepatic portosystemic shuntInternal MedicinemedicineRCT randomised controlled trialaRR adjusted risk ratioOClcsh:RC799-869quality controlalanine transferaseASTaRRHepatologybusiness.industryAutoimmunity; Cholestasis; Cirrhosis; Overlap PBC-AIHAIH autoimmune hepatitisTCC Treatment Completer CohortPBC primary biliary cholangitiGGTrisk ratioOC Overall cohortALPlcsh:Diseases of the digestive system. GastroenterologyPBC primary biliary cholangitisbusinessEDC

researchProduct

Pathogenic mechanisms of how human parvovirus breaks self-tolerance

2017

It is known that viral infections can cause acute, chronic, and autoimmune diseases (ADs). However, the mechanism of how a persistent viral infection contributes to ADs remains still unclear. In this thesis, pathological and immunological aspects of how common viruses can initiate autoimmunity were investigated, and human parvovirus B19 (B19V) was employed as a model virus. B19V non-structural protein 1 (NS1), a superfamily 3 (SF3) helicase, initiated DNA damage resulting in cellular apoptosis. The apoptotic bodies (ApoBods) induced by B19V NS1 were purified and characterized. These ApoBods contained viral NS1 proteins with modified autoimmune-associated self-antigens, e.g. DNA, Smith, Apol…

viruksetautoantibodiespatogeneesivirusesautoimmunityapoptosisvasta-aineetinfektiotautoimmuniteettiohjelmoitunut solukuolemaantigeenitimmunologianon-structural protein 1autovasta-aineethuman parvovirus B19apoptotic bodiesself-antigensparvovirukset

researchProduct

The interplay between the host microbiome and pathogenic viral infections

2021

The microorganisms associated with an organism, the microbiome, have a strong and wide impact in their host biology. In particular, the microbiome modulates both the host defense responses and immunity, thus influencing the fate of infections by pathogens. Indeed, this immune modulation and/or interaction with pathogenic viruses can be essential to define the outcome of viral infections. Understanding the interplay between the microbiome and pathogenic viruses opens future venues to fight viral infections and enhance the efficacy of antiviral therapies. An increasing number of researchers are focusing on microbiome-virus interactions, studying diverse combinations of microbial communities, …

virusesBiologyBacterial Physiological PhenomenaMicrobiologyViral infectionhost-microbiome interactionsInterferonImmunityVirologymedicineAnimalsHumansMicrobiomeOrganismhost-virus interactionsimmune modulationBacteriaHost (biology)pathogenesisMicrobiotainterferonImmune modulationQR1-502antiviral treatmentsVirus DiseasesImmunologyVirusesMicrobial InteractionsMinireviewmedicine.drugVirus Physiological Phenomena

researchProduct

Human Papillomavirus Type 16 E7 Peptide-Directed CD8+ T Cells from Patients with Cervical Cancer Are Cross-Reactive with the Coronavirus NS2 Protein

2003

ABSTRACTHuman papillomavirus type 16 (HPV16) E6 and E7 oncoproteins are required for cellular transformation and represent candidate targets for HPV-specific and major histocompatibility complex class I-restricted CD8+-T-cell responses in patients with cervical cancer. Recent evidence suggests that cross-reactivity represents the inherent nature of the T-cell repertoire. We identified HLA-A2 binding HPV16 E7 variant peptides from human, bacterial, or viral origin which are able to drive CD8+-T-cell responses directed against wild-type HPV16 E7 amino acid 11 to 19/20 (E711-19/20) epitope YMLDLQPET(T) in vitro. CD8+T cells reacting to the HLA-A2-presented peptide from HPV16 E711-19(20)recogni…

virusesPapillomavirus E7 ProteinsImmunologyMolecular Sequence DataPriming (immunology)Epitopes T-LymphocyteUterine Cervical NeoplasmsCD8-Positive T-LymphocytesCross ReactionsViral Nonstructural Proteinsmedicine.disease_causeMajor histocompatibility complexLymphocyte ActivationMicrobiologyEpitopeImmune systemVirologyHLA-A2 AntigenmedicineCytotoxic T cellHumansHuman coronavirus OC43Amino Acid SequencePapillomaviridaeCoronavirusbiologyPapillomavirus Infectionsvirus diseasesOncogene Proteins Viralbiology.organism_classificationVirologyMolecular biologyCoronavirusTumor Virus InfectionsInsect Sciencebiology.proteinPathogenesis and ImmunityFemalePeptidesCD8Journal of Virology

researchProduct

Immune responses during COVID-19 infection

2020

International audience; Over the past 16 years, three coronaviruses (CoVs), severe acute respiratory syndrome CoV (SARS-CoV) in 2002, Middle East respiratory syndrome CoV (MERS-CoV) in 2012 and 2015, and SARS-CoV-2 in 2020, have been causing severe and fatal human epidemics. The unpredictability of coronavirus disease-19 (COVID-19) poses a major burden on health care and economic systems across the world. This is caused by the paucity of in-depth knowledge of the risk factors for severe COVID-19, insufficient diagnostic tools for the detection of SARS-CoV-2, as well as the absence of specific and effective drug treatments. While protective humoral and cellular immune responses are usually m…

researchProduct